These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10706936)

  • 1. Antithrombotic properties of RWJ-50353, a potent and novel thrombin inhibitor.
    Giardino EC; Costanzo MJ; Kauffman JA; Li QS; Maryanoff BE; Andrade-Gordon P
    Thromb Res; 2000 Apr; 98(1):83-93. PubMed ID: 10706936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
    Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist.
    Damiano BP; Mitchell JA; Giardino E; Corcoran T; Haertlein BJ; de Garavilla L; Kauffman JA; Hoekstra WJ; Maryanoff BE; Andrade-Gordon P
    Thromb Res; 2001 Oct; 104(2):113-26. PubMed ID: 11672755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist.
    Herbert JM; Bernat A; Barthelemy G; Dol F; Rinaldi M
    Thromb Haemost; 1993 Mar; 69(3):262-7. PubMed ID: 8470049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
    Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
    J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
    Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
    Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-thrombotic Effects Mediated by a Novel Dual-Target Peptide Inhibiting Both Platelet Aggregation and Thrombin Activity without Causing Bleeding.
    Yu J; Wang T; Zhang X; Chen Q; Hu Y; Liang Q; Shi Y; Wang Y; Zhang Y; Yu M; Zhao B
    Thromb Haemost; 2024 Feb; 124(2):108-121. PubMed ID: 37657484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic properties of JJ1, a potent and novel thrombin inhibitor.
    Lee W; Lee S; Choi J; Park JH; Kim KM; Jee JG; Bae JS
    Sci Rep; 2017 Nov; 7(1):14862. PubMed ID: 29093471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis.
    Petzold T; Thienel M; Konrad I; Schubert I; Regenauer R; Hoppe B; Lorenz M; Eckart A; Chandraratne S; Lennerz C; Kolb C; Braun D; Jamasbi J; Brandl R; Braun S; Siess W; Schulz C; Massberg S
    Sci Transl Med; 2016 Nov; 8(367):367ra168. PubMed ID: 27903864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.
    Lu T; Markotan T; Ballentine SK; Giardino EC; Spurlino J; Crysler CS; Brown K; Maryanoff BE; Tomczuk BE; Damiano BP; Shukla U; End D; Andrade-Gordon P; Bone RF; Player MR
    J Med Chem; 2010 Feb; 53(4):1843-56. PubMed ID: 20102150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
    Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
    Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic effects of the novel inhibitor of thrombin-induced offtelet aggregation and thrombus formation, 3-[2-[1,1':2',1"]-terphenyl-4'-yl)ethyl]phenoxyacetic acid.
    Miyamae T; Hashizume H; Ogawa T; Okayama T; Nukui E; Oshima K; Morikawa T; Hagiwara M
    Arzneimittelforschung; 1997 Jan; 47(1):13-8. PubMed ID: 9037437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bothrojaracin, a new thrombin inhibitor isolated from Bothrops jararaca venom: characterization and mechanism of thrombin inhibition.
    Zingali RB; Jandrot-Perrus M; Guillin MC; Bon C
    Biochemistry; 1993 Oct; 32(40):10794-802. PubMed ID: 8399228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress.
    Uemura T; Kawasaki T; Taniguchi M; Moritani Y; Hayashi K; Saito T; Takasaki J; Uchida W; Miyata K
    Br J Pharmacol; 2006 May; 148(1):61-9. PubMed ID: 16520742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors.
    Leblond L; Grouix B; Boudreau C; Yang Q; Siddiqui MA; Winocour PD
    Thromb Res; 2000 Nov; 100(3):195-209. PubMed ID: 11108907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
    Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-platelet and anti-thrombosis characteristics of Z4A5, a novel selective platelet glycoprotein IIb/IIIa inhibitor, compared with eptifibatide under long-term infusion.
    Shi XL; Shen S; Guo MM; Zhang GJ; Che J; Wang B; Zhou J
    Pharmazie; 2015 Dec; 70(12):810-4. PubMed ID: 26817279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.